VERTEX PHARMACEUTICALS INC / MA
VRTXOther · Large accelerated filer · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $12.00B | $11.02B | $9.87B | $8.93B | $7.57B | $6.21B |
| Operating income | $4.17B | −$232.9M | $3.83B | $4.31B | $2.78B | $2.86B |
| Net income | $3.95B | −$535.6M | $3.62B | $3.32B | $2.34B | $2.71B |
| Total assets | $25.64B | $22.53B | $22.73B | $18.15B | $13.43B | $11.75B |
| Total liabilities | $6.98B | $6.12B | $5.15B | $4.24B | $3.33B | $3.06B |
| Equity | $18.67B | $16.41B | $17.58B | $13.91B | $10.10B | $8.69B |
| EPS (diluted) | $15.32 | $-2.08 | $13.89 | $12.82 | $9.01 | $10.29 |
| Shares out. | 256.8M | 258.3M | 257.1M | 254.6M | 260.0M | 259.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 34.8%
- Net margin
- 32.9%
- Return on equity
- 21.2%
- Return on assets
- 15.4%
- Return on capital (ROCE)
- 19.2%
- Liabilities / assets
- 27.2%
- Debt / equity
- 0.37×
- Book value / share
- $72.69
- Revenue growth (YoY)
- 8.9%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 7.50safe
- Accruals / assets
- 1.3%clean
- Piotroski F-Score
- 6/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 7 good- Operating margin is positive
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Capital World InvestorsPassive (13G)May 14, 2026
- Capital Research Global InvestorsPassive (13G)May 14, 2026
- Vanguard Capital Management LlcPassive (13G)Apr 30, 2026
- Vanguard Group IncPassive (13G)Mar 27, 2026
- Fmr LlcPassive (13G)Feb 12, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Bunnage Mark E.Officer — EVP, Chief Scientific Officer | May 15, 2026 | Sell | 33 | $453.45 |
| Bozic CarmenOfficer — EVP and CMO | May 15, 2026 | Sell | 1,354 | $453.45 |
| Bozic CarmenOfficer — EVP and CMO | May 12, 2026 | Sell | 6,988 | $450.00 |
| Upadhyay SuketuDirector | May 1, 2026 | D | 796 | — |
| Thornberry NancyDirector | May 1, 2026 | Grant | 472 | $0.00 |
| Schneider JenniferDirector | May 1, 2026 | Grant | 472 | $0.00 |
| Mckenzie DianaDirector | May 1, 2026 | Grant | 943 | $0.00 |
| Liu JoyOfficer — EVP and Chief Legal Officer | May 1, 2026 | Sell | 1,104 | $425.02 |
| Garber Alan MDirector | May 1, 2026 | Grant | 472 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 4.5M | 3.6 | +6.9% |
| Apr 30, 2026 | 4.2M | 4.3 | -3.8% |
| Apr 15, 2026 | 4.3M | 3.8 | +7.8% |
| Mar 31, 2026 | 4.0M | 2.7 | -2.6% |
| Mar 13, 2026 | 4.1M | 2.9 | -6.9% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer change · Shareholder voteMay 13, 2026
- Results of operationsMay 4, 2026
- Director / officer changeApr 29, 2026
- Other material eventMar 31, 2026
- Results of operationsFeb 12, 2026
- Results of operationsNov 3, 2025
- Results of operations · Director / officer changeAug 4, 2025
- Other material eventMay 19, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.